In the Phase 2 ALPACA study, Lp(a) levels were reduced from baseline by up to 93.9% compared to placebo, from day 60 to 180, after a single dose of the investigational siRNA, lepodisiran.1 Sustained reductions of up to 53.4% were recorded at 540 days after a single dose and 74.2% at 540 days following a second dose at day 180.
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.